Putative class plaintiffs alleging Eli Lilly & Co. misrepresented the frequency of Cymbalta withdrawal symptoms failed to show damages could be proven classwide, the Central District of California ruled (Saavedra v. Eli Lilly & Co., C.D. Cal., 12-09366, 12/18/14).
The U.S. District Court for the Central District of California Dec. 18 declined to certify a class in the consumer suit.
Plaintiffs Jennifer Saavedra and others alleged they were harmed because Lilly understated the risk of withdrawal-related side effects, so they received a product that had less value than they expected it to have.
They sought to represent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.